Trans Genic Inc. (2342.T)
JPY 183.0
(-1.08%)
JPY 183.0
(-1.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.08 Million JPY | 101.0% |
| 2022 | -409.66 Million JPY | -121.83% |
| 2021 | 1.87 Billion JPY | 243.47% |
| 2020 | 546.28 Million JPY | 224.16% |
| 2019 | -440 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -99 Million JPY | -333.49% |
| 2023 Q2 | -29.73 Million JPY | -138.03% |
| 2023 FY | 4.08 Million JPY | 101.0% |
| 2023 Q3 | -86.78 Million JPY | -191.82% |
| 2023 Q1 | 78.2 Million JPY | 113.22% |
| 2023 Q4 | 42.4 Million JPY | 148.86% |
| 2022 Q3 | 127.16 Million JPY | 57.68% |
| 2022 FY | -409.66 Million JPY | -121.83% |
| 2022 Q4 | -591.72 Million JPY | -565.31% |
| 2022 Q2 | 80.64 Million JPY | 0.0% |
| 2021 FY | 1.87 Billion JPY | 243.47% |
| 2020 FY | 546.28 Million JPY | 224.16% |
| 2019 FY | -440 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 98.936% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 100.775% |
| GNI Group Ltd. | 8.09 Billion JPY | 99.95% |
| Linical Co., Ltd. | 338.26 Million JPY | 98.792% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 100.284% |
| Soiken Holdings Inc. | -662.2 Million JPY | 100.617% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 97.043% |
| AnGes, Inc. | -7.43 Billion JPY | 100.055% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 100.317% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 100.057% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 97.812% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 100.524% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 100.354% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 100.338% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 100.503% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 101.262% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 100.335% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 100.287% |
| PeptiDream Inc. | 3.03 Billion JPY | 99.865% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 100.211% |
| Ribomic Inc. | -1.02 Billion JPY | 100.399% |
| SanBio Company Limited | -2.64 Billion JPY | 100.155% |
| Healios K.K. | -3.82 Billion JPY | 100.107% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 100.35% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 100.274% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 100.286% |
| StemRIM | -2.02 Billion JPY | 100.202% |
| CellSource Co., Ltd. | 923.14 Million JPY | 99.557% |
| FunPep Company Limited | -933.41 Million JPY | 100.438% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 100.478% |
| Stella Pharma Corporation | -763.74 Million JPY | 100.535% |
| TMS Co., Ltd. | -960.04 Million JPY | 100.426% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 100.361% |
| Cuorips Inc. | -632.18 Million JPY | 100.646% |
| K Pharma,Inc. | 260.33 Million JPY | 98.431% |
| Takara Bio Inc. | 1.48 Billion JPY | 99.724% |
| ReproCELL Incorporated | -31.41 Million JPY | 113.003% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 84.514% |
| StemCell Institute Inc. | 310.98 Million JPY | 98.686% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 97.147% |
| CellSeed Inc. | -846.53 Million JPY | 100.483% |